Literature DB >> 7108444

Cooperative interaction of factor B and other complement components with mononuclear cells in the antibody-independent lysis of xenogeneic erythrocytes.

R E Hall, R M Blaese, A E Davis, J M Decker, B F Tack, H R Colten, A V Muchmore.   

Abstract

Synergistic cytotoxicity is a term used to describe a cytotoxic system in which xenogeneic erythrocyte target cells are lysed in the presence of nonimmune human mononuclear effector cells and antibody-depleted normal human serum. Neither the mononuclear cells nor the serum alone are cytolytic to the target erythrocytes. Previous studies have shown that the serum activity is not immunoglobulin and is heat-labile, suggesting a similarity to serum complement. In this report, sera deficient in various complement components as well as highly purified single complement components were tested with whole mononuclear cell populations and purified monocytes and lymphocytes to further characterize this cytotoxicity system. Whole mononuclear cell populations failed to mediate target cell lysis in sera deficient in C5 or factor B. However, C3-deficient serum, even in the presence of anti-C3 antibody, supported synergistic cytotoxicity normally. Purified lymphocytes were also normally cytotoxic in C3-deficient serum but failed to lyse targets in sera deficient in C5, C7, C8, or depleted of factor B. Purified monocytes failed to lyse the target cells only in factor B-depleted serum and could lyse the target cells in serum-free medium when purified factor B alone was added. Monocyte-mediated cytotoxicity induced by factor B was inhibited 73-100% by adding lymphocytes back to the purified monocytes. Thus, both lymphocytes and monocytes can serve as effector cells in this form of cytotoxicity but require cooperative interaction with different sets of complement components. In addition, lymphocytes can modulate the monocyte-mediated form of target cell lysis associated with factor B.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 7108444      PMCID: PMC2186781          DOI: 10.1084/jem.156.3.834

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  16 in total

1.  Biosynthetic defect in monocytes from human beings with genetic deficiency of the second component of complement.

Authors:  L P Einstein; C A Alper; K J Bloch; J T Herrin; F S Rosen; J R David; H R Colten
Journal:  N Engl J Med       Date:  1975-05-29       Impact factor: 91.245

2.  Hereditary deficiency of the fifth component of complement in man. I. Clinical, immunochemical, and family studies.

Authors:  S I Rosenfeld; M E Kelly; J P Leddy
Journal:  J Clin Invest       Date:  1976-06       Impact factor: 14.808

3.  Homozygous deficiency of C3 in a patient with repeated infections.

Authors:  C A Alper; H R Colten; F S Rosen; A R Rabson; G M Macnab; J S Gear
Journal:  Lancet       Date:  1972-12-02       Impact factor: 79.321

4.  Synergistic cytotoxicity. II. In vitro arming of monocytes and T cells by a heat labile fraction of human plasma.

Authors:  A V Muchmore; J M Decker; R M Blaese
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

5.  Immunoaffinity chromatography of proteins.

Authors:  D M Livingston
Journal:  Methods Enzymol       Date:  1974       Impact factor: 1.600

6.  Biosynthesis of complement by human monocytes.

Authors:  D W Beatty; A E Davis; F S Cole; L P Einstein; H R Colten
Journal:  Clin Immunol Immunopathol       Date:  1981-03

7.  Complete absence of the third component of complement in man.

Authors:  M Ballow; J E Shira; L Harden; S Y Yang; N K Day
Journal:  J Clin Invest       Date:  1975-09       Impact factor: 14.808

8.  In vivo studies in C4-deficient guinea pigs.

Authors:  L Ellman; I Green; F Judge; M M Frank
Journal:  J Exp Med       Date:  1971-07-01       Impact factor: 14.307

9.  In vitro synthesis of some complement components (C1q, C3 and C4) by lymphoid tissues and circulating leucocytes in man.

Authors:  R F Lai A Fat; R van Furth
Journal:  Immunology       Date:  1975-02       Impact factor: 7.397

10.  Synergistic cytotoxicity. I. Characterization of a heat labile plasma fraction that induces nonspecific cytotoxicity by human mononuclear cells.

Authors:  A V Muchmore; J M Decker; R M Blaese
Journal:  J Immunol       Date:  1979-03       Impact factor: 5.422

View more
  5 in total

Review 1.  Molecular genetics of the major histocompatibility linked complement genes.

Authors:  H R Colten
Journal:  Springer Semin Immunopathol       Date:  1983

Review 2.  Complement components in relation to macrophage function.

Authors:  H P Hartung; U Hadding
Journal:  Agents Actions       Date:  1983-08

3.  Abrogation of the alternative complement pathway by targeted deletion of murine factor B.

Authors:  M Matsumoto; W Fukuda; A Circolo; J Goellner; J Strauss-Schoenberger; X Wang; S Fujita; T Hidvegi; D D Chaplin; H R Colten
Journal:  Proc Natl Acad Sci U S A       Date:  1997-08-05       Impact factor: 11.205

4.  cis and trans elements differ among mouse strains with high and low extrahepatic complement factor B gene expression.

Authors:  G Garnier; B Ault; M Kramer; H R Colten
Journal:  J Exp Med       Date:  1992-02-01       Impact factor: 14.307

5.  Factor B, the complement alternative pathway serine proteinase, is a major constitutive protein synthesized and secreted by resident and elicited mouse macrophages.

Authors:  J S Sundsmo; J R Chin; R A Papin; D S Fair; Z Werb
Journal:  J Exp Med       Date:  1985-02-01       Impact factor: 14.307

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.